Re-confirm 70 mg + 3 mL = 23.33 mg/mL and that draws are truly 10 units
Potential benefits of using GLP-1 receptor agonists after gastric sleeve surgery include: Enhanced weight loss : Observational studies suggest post-bariatric patients using GLP-1 receptor agonists may achieve additional weight reduction, typically around 510% of body weight, though individual responses vary considerably Improved glycaemic control : Particularly beneficial for patients with type 2 diabetes or prediabetes, as GLP-1 agonists enhance insulin secretion and reduce blood glucose levels Reduced appetite : These medications can help patients who struggle with persistent hunger despite surgical intervention Cardiovascular benefits : Semaglutide has demonstrated cardiovascular risk reduction in people with established cardiovascular disease, which may benefit eligible post-bariatric patients with this specific risk profile Maintenance of weight loss : May help prevent weight regain during the critical maintenance phase Potential risks and considerations include: Gastrointestinal side effects : Nausea, vomiting, diarrhoea, and constipation are common, particularly during dose escalation
Notably, it has a prominent effect on alcohol lesions (i.e., acute, chronic) and NSAIDs-lesions (interestingly, BPC 157 both prevents and reverses arthritis) and acts as a free radical scavenger and exhibits neuroprotective properties
Khavinson VK, Bondarev IE, Butyugov AA
Given that peptides play an effective role in improving the composition of the gut microbiota, maintaining homeostasis of the gut microbiota prevents or delays the onset of neurodegenerative diseases
Headaches GLP-1-related headaches occur in a subset of users, typically during the first few weeks or after dose escalation
